The effects of antiglaucoma and systemic medications on ocular blood flow

Vital P. Costa, Alon Harris, Einar Stefánsson, Josef Flammer, Gunter K. Krieglstein, Nicola Orzalesi, Anders Heijl, Jean Paul Renard, Luis Metzner Serra

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Based on the body of evidence implicating ocular blood flow disturbances in the pathogenesis of glaucoma, there is great interest in the investigation of the effects of antiglaucoma drugs and systemic medications on the various ocular vascular beds. The primary aim of this article was to review the current data available on the effects of antiglaucoma drugs and systemic medications on ocular blood flow. We performed a literature search in November 2002, which consisted of a textword search in MEDLINE for the years 1968-2002. The results of this review suggest that there is a severe lack of well-designed long-term studies investigating the effects of antiglaucoma and systemic medications on ocular blood flow in glaucomatous patients. However, among the 136 articles dealing with the effect of antiglaucoma drugs on ocular blood flow, only 36 (26.5%) investigated the effects of medications on glaucoma patients. Among these 36 articles, only 3 (8.3%) were long-term studies, and only 16 (44.4%) were double-masked, randomized, prospective trials. Among the 33 articles describing the effects of systemic medications on ocular blood flow, only 11 (33.3%) investigated glaucoma patients, of which only one (9.1%) was a double-masked, randomized, prospective trial. Based on this preliminary data, we would intimate that few antiglaucoma medications have the potential to directly improve ocular blood flow. Unoprostone appears to have a reproducible antiendothelin-1 effect, betaxolol may exert a calcium-channel blocker action, apraclonidine consistently leads to anterior segment vasoconstriction, and carbonic anhydrase inhibitors seem to accelerate the retinal circulation. Longitudinal, prospective, randomized trials are needed to investigate the effects of vasoactive substances with no hypotensive effect on the progression of glaucoma.

Original languageEnglish
Pages (from-to)769-805
Number of pages37
JournalProgress in Retinal and Eye Research
Volume22
Issue number6
DOIs
StatePublished - Nov 2003

Fingerprint

Glaucoma
Betaxolol
Pharmaceutical Preparations
Carbonic Anhydrase Inhibitors
Calcium Channel Blockers
Vasoconstriction
MEDLINE
Blood Vessels

ASJC Scopus subject areas

  • Sensory Systems
  • Ophthalmology

Cite this

Costa, V. P., Harris, A., Stefánsson, E., Flammer, J., Krieglstein, G. K., Orzalesi, N., ... Serra, L. M. (2003). The effects of antiglaucoma and systemic medications on ocular blood flow. Progress in Retinal and Eye Research, 22(6), 769-805. https://doi.org/10.1016/S1350-9462(03)00064-8

The effects of antiglaucoma and systemic medications on ocular blood flow. / Costa, Vital P.; Harris, Alon; Stefánsson, Einar; Flammer, Josef; Krieglstein, Gunter K.; Orzalesi, Nicola; Heijl, Anders; Renard, Jean Paul; Serra, Luis Metzner.

In: Progress in Retinal and Eye Research, Vol. 22, No. 6, 11.2003, p. 769-805.

Research output: Contribution to journalArticle

Costa, VP, Harris, A, Stefánsson, E, Flammer, J, Krieglstein, GK, Orzalesi, N, Heijl, A, Renard, JP & Serra, LM 2003, 'The effects of antiglaucoma and systemic medications on ocular blood flow', Progress in Retinal and Eye Research, vol. 22, no. 6, pp. 769-805. https://doi.org/10.1016/S1350-9462(03)00064-8
Costa, Vital P. ; Harris, Alon ; Stefánsson, Einar ; Flammer, Josef ; Krieglstein, Gunter K. ; Orzalesi, Nicola ; Heijl, Anders ; Renard, Jean Paul ; Serra, Luis Metzner. / The effects of antiglaucoma and systemic medications on ocular blood flow. In: Progress in Retinal and Eye Research. 2003 ; Vol. 22, No. 6. pp. 769-805.
@article{ecefdedf9372450abe71d4679df0c1e6,
title = "The effects of antiglaucoma and systemic medications on ocular blood flow",
abstract = "Based on the body of evidence implicating ocular blood flow disturbances in the pathogenesis of glaucoma, there is great interest in the investigation of the effects of antiglaucoma drugs and systemic medications on the various ocular vascular beds. The primary aim of this article was to review the current data available on the effects of antiglaucoma drugs and systemic medications on ocular blood flow. We performed a literature search in November 2002, which consisted of a textword search in MEDLINE for the years 1968-2002. The results of this review suggest that there is a severe lack of well-designed long-term studies investigating the effects of antiglaucoma and systemic medications on ocular blood flow in glaucomatous patients. However, among the 136 articles dealing with the effect of antiglaucoma drugs on ocular blood flow, only 36 (26.5{\%}) investigated the effects of medications on glaucoma patients. Among these 36 articles, only 3 (8.3{\%}) were long-term studies, and only 16 (44.4{\%}) were double-masked, randomized, prospective trials. Among the 33 articles describing the effects of systemic medications on ocular blood flow, only 11 (33.3{\%}) investigated glaucoma patients, of which only one (9.1{\%}) was a double-masked, randomized, prospective trial. Based on this preliminary data, we would intimate that few antiglaucoma medications have the potential to directly improve ocular blood flow. Unoprostone appears to have a reproducible antiendothelin-1 effect, betaxolol may exert a calcium-channel blocker action, apraclonidine consistently leads to anterior segment vasoconstriction, and carbonic anhydrase inhibitors seem to accelerate the retinal circulation. Longitudinal, prospective, randomized trials are needed to investigate the effects of vasoactive substances with no hypotensive effect on the progression of glaucoma.",
author = "Costa, {Vital P.} and Alon Harris and Einar Stef{\'a}nsson and Josef Flammer and Krieglstein, {Gunter K.} and Nicola Orzalesi and Anders Heijl and Renard, {Jean Paul} and Serra, {Luis Metzner}",
year = "2003",
month = "11",
doi = "10.1016/S1350-9462(03)00064-8",
language = "English",
volume = "22",
pages = "769--805",
journal = "Progress in Retinal and Eye Research",
issn = "1350-9462",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - The effects of antiglaucoma and systemic medications on ocular blood flow

AU - Costa, Vital P.

AU - Harris, Alon

AU - Stefánsson, Einar

AU - Flammer, Josef

AU - Krieglstein, Gunter K.

AU - Orzalesi, Nicola

AU - Heijl, Anders

AU - Renard, Jean Paul

AU - Serra, Luis Metzner

PY - 2003/11

Y1 - 2003/11

N2 - Based on the body of evidence implicating ocular blood flow disturbances in the pathogenesis of glaucoma, there is great interest in the investigation of the effects of antiglaucoma drugs and systemic medications on the various ocular vascular beds. The primary aim of this article was to review the current data available on the effects of antiglaucoma drugs and systemic medications on ocular blood flow. We performed a literature search in November 2002, which consisted of a textword search in MEDLINE for the years 1968-2002. The results of this review suggest that there is a severe lack of well-designed long-term studies investigating the effects of antiglaucoma and systemic medications on ocular blood flow in glaucomatous patients. However, among the 136 articles dealing with the effect of antiglaucoma drugs on ocular blood flow, only 36 (26.5%) investigated the effects of medications on glaucoma patients. Among these 36 articles, only 3 (8.3%) were long-term studies, and only 16 (44.4%) were double-masked, randomized, prospective trials. Among the 33 articles describing the effects of systemic medications on ocular blood flow, only 11 (33.3%) investigated glaucoma patients, of which only one (9.1%) was a double-masked, randomized, prospective trial. Based on this preliminary data, we would intimate that few antiglaucoma medications have the potential to directly improve ocular blood flow. Unoprostone appears to have a reproducible antiendothelin-1 effect, betaxolol may exert a calcium-channel blocker action, apraclonidine consistently leads to anterior segment vasoconstriction, and carbonic anhydrase inhibitors seem to accelerate the retinal circulation. Longitudinal, prospective, randomized trials are needed to investigate the effects of vasoactive substances with no hypotensive effect on the progression of glaucoma.

AB - Based on the body of evidence implicating ocular blood flow disturbances in the pathogenesis of glaucoma, there is great interest in the investigation of the effects of antiglaucoma drugs and systemic medications on the various ocular vascular beds. The primary aim of this article was to review the current data available on the effects of antiglaucoma drugs and systemic medications on ocular blood flow. We performed a literature search in November 2002, which consisted of a textword search in MEDLINE for the years 1968-2002. The results of this review suggest that there is a severe lack of well-designed long-term studies investigating the effects of antiglaucoma and systemic medications on ocular blood flow in glaucomatous patients. However, among the 136 articles dealing with the effect of antiglaucoma drugs on ocular blood flow, only 36 (26.5%) investigated the effects of medications on glaucoma patients. Among these 36 articles, only 3 (8.3%) were long-term studies, and only 16 (44.4%) were double-masked, randomized, prospective trials. Among the 33 articles describing the effects of systemic medications on ocular blood flow, only 11 (33.3%) investigated glaucoma patients, of which only one (9.1%) was a double-masked, randomized, prospective trial. Based on this preliminary data, we would intimate that few antiglaucoma medications have the potential to directly improve ocular blood flow. Unoprostone appears to have a reproducible antiendothelin-1 effect, betaxolol may exert a calcium-channel blocker action, apraclonidine consistently leads to anterior segment vasoconstriction, and carbonic anhydrase inhibitors seem to accelerate the retinal circulation. Longitudinal, prospective, randomized trials are needed to investigate the effects of vasoactive substances with no hypotensive effect on the progression of glaucoma.

UR - http://www.scopus.com/inward/record.url?scp=0142058595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142058595&partnerID=8YFLogxK

U2 - 10.1016/S1350-9462(03)00064-8

DO - 10.1016/S1350-9462(03)00064-8

M3 - Article

VL - 22

SP - 769

EP - 805

JO - Progress in Retinal and Eye Research

JF - Progress in Retinal and Eye Research

SN - 1350-9462

IS - 6

ER -